MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Phase 2
Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2023-04-21
Last Posted Date
2024-07-26
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
46
Registration Number
NCT05823012
Locations
🇺🇸

Panax Clinical Research, LLC, Miami Lakes, Florida, United States

🇺🇸

American Research Corporation, San Antonio, Texas, United States

🇺🇸

Rainier Clinical Research Center, Renton, Washington, United States

and more 3 locations

Effect of Acupuncture and Low Caloric Diet on Primary Hypothyroidism and Irregular Menstruation in Infertile Women

Phase 2
Completed
Conditions
Primary Hypothyroidism
Acupuncture
Irregular Menstruation
PCO
Interventions
Device: acupuncture
Dietary Supplement: low caloric diet
First Posted Date
2023-04-07
Last Posted Date
2023-04-07
Lead Sponsor
Cairo University
Target Recruit Count
60
Registration Number
NCT05804149
Locations
🇪🇬

Eman Sedky, Cairo, Maadi, Egypt

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

Phase 2
Active, not recruiting
Conditions
Hypothyroidism
Interventions
Drug: North Star
First Posted Date
2023-02-03
Last Posted Date
2025-05-14
Lead Sponsor
Neuvosyn Laboratories, LLC
Target Recruit Count
300
Registration Number
NCT05712421
Locations
🇺🇸

Neuvosyn Investigational Site, Stafford, Texas, United States

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Phase 2
Recruiting
Conditions
Liver Fibrosis
Nonalcoholic Steatohepatitis
Interventions
Drug: Placebo
First Posted Date
2022-09-02
Last Posted Date
2025-02-24
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
128
Registration Number
NCT05526144
Locations
🇺🇸

Harry S. Truman Memorial, Columbia, MO, Columbia, Missouri, United States

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Phase 2
Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2022-06-09
Last Posted Date
2024-08-26
Lead Sponsor
Sention Therapeutics, LLC
Target Recruit Count
490
Registration Number
NCT05412979
Locations
🇺🇸

Sention Investigational Site, Renton, Washington, United States

Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19

Completed
Conditions
Thyroid Dysfunction
Hypothyroidism
Hyperthyroidism
Interventions
First Posted Date
2022-05-23
Last Posted Date
2022-05-23
Lead Sponsor
OMER B ABDELBASIT
Target Recruit Count
95
Registration Number
NCT05385029
Locations
🇸🇦

Security Forces Hospital, Riyadh, Central, Saudi Arabia

Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism

Phase 4
Completed
Conditions
Congenital Hypothyroidism
Interventions
First Posted Date
2022-05-12
Last Posted Date
2022-05-12
Lead Sponsor
Federico II University
Target Recruit Count
72
Registration Number
NCT05371262

TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients

Phase 3
Recruiting
Conditions
Hypothyroidism; Irradiation
Interventions
First Posted Date
2022-04-07
Last Posted Date
2023-12-06
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
68
Registration Number
NCT05316922
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Recovery Rate in Secondary Hypothyroidism

Recruiting
Conditions
Secondary Hypothyroidism
First Posted Date
2022-03-11
Last Posted Date
2024-08-21
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
90
Registration Number
NCT05276856
Locations
🇨🇦

Nova Scotia Health, Halifax, Canada

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.

Phase 4
Conditions
Thyroid Cancer, Papillary
Hypothyroidism
Interventions
Drug: L-T4+T3 (thyroid tablet)
First Posted Date
2022-02-18
Last Posted Date
2022-02-18
Lead Sponsor
Zhongshan Hospital Xiamen University
Target Recruit Count
50
Registration Number
NCT05247476
Locations
🇨🇳

Yan Ling, Xiamen, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath